Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Holding MLYS?
Track your performance easily
See the Price Targets and Ratings of:
MLYS Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLYS Stock 12 Month Forecast
Average Price Target
$33.50
▲(171.47% Upside)
| Highest Price Target$45.00 | Average Price Target$33.50 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
Reiterated
11/12/24
Stifel Nicolaus
Reiterated
11/12/24
H.C. Wainwright
Reiterated
11/12/24
Wells Fargo
Reiterated
11/11/24
Goldman Sachs
$29
Buy
135.01%
Upside
Reiterated
08/14/24
Goldman Sachs reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)Goldman Sachs analyst Richard Law reiterated a Buy rating and $29.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
Guggenheim
―
Buy
―
Reiterated
06/28/24
We maintain our confidence in the ASI class (which includes 3 active late stage programs) and in the thoughtful development approach of lorundrostat, which has its first pivotal Ph2 Advance readout in 4Q24. We recommend investors BUY MLYS ahead of the ADVANCE-HTN data coming before YE2024.
Citi
$36
Buy
191.73%
Upside
Reiterated
05/13/24
Bank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Scotiabank
$36
Buy
191.73%
Upside
Reiterated
03/21/24
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Mineralys Therapeutics, Inc. (NASDAQ: MLYS) and Addus Homecare (NASDAQ: ADUS)
Best Analysts Covering Mineralys Therapeutics, Inc.
Which Analyst Should I Follow If I Want to Buy MLYS and Sell After:
1 Month
xxx
Success Rate
2/8 ratings generated profit
Average Return
-6.19%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of -6.19% per trade.
3 Months
xxx
Success Rate
2/8 ratings generated profit
Average Return
-11.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -11.84% per trade.
1 Year
Success Rate
2/8 ratings generated profit
Average Return
-9.99%
reiterated a buy rating last month
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -9.99% per trade.
2 Years
xxx
Success Rate
1/8 ratings generated profit
Average Return
-12.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -12.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLYS Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
6
8
6
8
7
Buy
2
2
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
7
9
8
Each month's total comprises the sum of three months' worth of ratings.
MLYS Financial Forecast
MLYS Stock Forecast FAQ
What is MLYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Mineralys Therapeutics, Inc.’s 12-month average price target is $33.50.
What is MLYS’s upside potential, based on the analysts’ average price target?
Mineralys Therapeutics, Inc. has 171.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLYS a Buy, Sell or Hold?
Mineralys Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mineralys Therapeutics, Inc.’s price target?
The average price target for Mineralys Therapeutics, Inc. is $33.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 171.47% Increase from the current price of $12.34.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 171.47% Increase from the current price of $12.34.
What do analysts say about Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of MLYS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.